TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute to Participate at Upcoming Investor Conferences

The Oncology Institute to Participate at Upcoming Investor Conferences

CERRITOS, Calif., May 29, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:

Jefferies Global Healthcare Conference

Date: June 6th, 2024

Fireside Chat: 9:00am Eastern Time

TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer

Location: New York City, NY

Truist Securities Healthcare Disruptors & Digital Health Summit

Date: June 26th, 2024

Panel: 1:00pm Eastern Time

TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer

Location: New York City, NY

Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at /. The online replay will be available for a limited time shortly following the call.

About The Oncology Institute, Inc.

Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

Contacts

Investors

Solebury Strategic Communications



EN
29/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

 PRESS RELEASE

The Oncology Institute to Participate in Multiple Healthcare Investor ...

The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that members of its executive leadership team will participate in several investor conferences in March. Details for the conferences are as follows: Jefferies Healthcare Services Innovation & Technology SummitPresentation: Monday, March 9, 2026, from 11:30 a.m. to 12:00 p.m. ETLocation: Miami, FLPresenter: Dr. Daniel Virnich, Chief Execut...

 PRESS RELEASE

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO r...

 PRESS RELEASE

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminar...

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch